Functional divergence of the two Elongator subcomplexes during neurodevelopment


Abstract

The highly conserved Elongator complex is a translational regulator that plays a critical role in neurodevelopment, neurological diseases, and brain tumors. Numerous clinically relevant variants have been reported in the catalytic Elp123 subcomplex, while no missense mutations in the accessory subcomplex Elp456 have been described. Here, we identify ELP4 and ELP6 variants in patients with developmental delay, epilepsy, intellectual disability, and motor dysfunction. We determine the structures of human and murine Elp456 subcomplexes and locate the mutated residues. We show that patient-derived mutations in Elp456 affect the tRNA modification activity of Elongator in vitro as well as in human and murine cells. Modeling the pathogenic variants in mice recapitulates the clinical features of the patients and reveals neuropathology that differs from the one caused by previously characterized Elp123 mutations. Our study demonstrates a direct correlation between Elp4 and Elp6 mutations, reduced Elongator activity, and neurological defects. Foremost, our data indicate previously unrecognized differences of the Elp123 and Elp456 subcomplexes for individual tRNA species, in different cell types and in different key steps during the neurodevelopment of higher organisms.

Keywords Elongator complex; Elp4; Elp6; neurodevelopment; tRNA modification

Introduction

Neurodevelopmental disorders (NDDs) such as global development delay, intellectual disability (ID), and epilepsy are characterized by...
developmental deficits in cognition, learning, control, and execution of motor skills due to abnormalities in the brain development (Parenti et al., 2020). High co-occurrence of NDDs indicates a shared underlying molecular cause of certain groups of pathologies. Despite major efforts in the field to find the genes driving the various subgroups of disorders, the phenotypic heterogeneity of these conditions impedes the confident identification of common genetic factors (Hormozdiari et al., 2015; Chow et al., 2019; Carvill et al., 2021; Peng et al., 2021).

Elongator is a large and highly conserved multi-subunit macromolecular complex that acts as a global translational regulator by modifying the so-called “wobble” base (U34) in the anticodon of 12 mammalian tRNAs to form 5-carboxymethyl-uridine (cm5U34). Subsequently, cm5U34 can be converted into either 5-carbamoylmethyl-uridine (ncm5U34), 5-methoxycarbonylmethyl-uridine (mcm5U34), or 5-methoxycarbonylmethyl-2-thiouridine (mcm5s2U34) (Schäck et al., 2020) by other enzymes. All of these modifications have a strong impact on the kinetics of translation elongation by regulating efficiency and accuracy of codon-anticodon pairing in the A-site of ribosomes (Nedialkova & Leidel, 2015). Elongator consists of two copies of each of the six subunits (Elp1-6) and forms two discrete subcomplexes, namely Elp123 and Elp456 (Dauden et al., 2017). In yeast, each of the six subunits is equally important for the integrity and function of the fully assembled Elongator complex. The Elp123 subcomplex acts as a scaffold for the Elp3 subunit, which catalyzes the actual RNA base modification reaction (Dauden et al., 2019; Lin et al., 2019). The hetero-hexameric ELP456 subcomplex is attached asymmetrically to Elp123 (Dauden et al., 2017) and forms a ring-like structure that possesses adenosine triphosphatase hydrolysis (ATPase) activity and regulates tRNA binding (Glatt et al., 2012; Dauden et al., 2019).

A growing body of evidence indicates that the Elongator complex is one of the master regulators of neurodevelopment in higher eukaryotes (Kojic & Wainwright, 2016; Hawer et al., 2018). Pathogenic variants in Elongator subunits have been identified in a number of cases with severe and complex NDDs, including ELP1 pathogenic variants in familial dysautonomia (FD) (Anderson et al., 2001; Slaugenhaupt et al., 2001), ELP3 variants associated with amyotrophic lateral sclerosis (ALS) (Simpson et al., 2009; Kwée et al., 2012), and pathogenic variants in ELP2 found in patients with global developmental delay, ID, autism, and epilepsy (Strug et al., 2009; Najmabadi et al., 2011; Reinthaler et al., 2014; Addis et al., 2015; Cohen et al., 2015; Alizadeh et al., 2018; Toral-Lopez et al., 2020; Kojic et al., 2021). In addition, the ELP4-PAHX6 locus has been linked to Rolandic epilepsy (Panjwani et al., 2016; Duan et al., 2021), which was questioned by others (Reinthaler et al., 2014). As the genomic alterations seem to affect the non-coding and intronic regions, the ELP4 protein remains most likely unaffected, and the misregulation of PAX6 seems more likely to cause the condition (Panjwani et al., 2016). Decreased levels of mcm5s2U34 have been found in FD (Karlsborn et al., 2014) and ALS (Bento-Abreu et al., 2018) patients, indicating that impairment of tRNA modification could directly drive the underlying diseases. Our current understanding of the role of the Elongator complex in guiding brain development and disease is largely limited to results from conditional loss-of-function (LOF) mouse models and primarily mutations in the catalytic Elp123 subcomplex (Lagousse et al., 2015; Chaverra et al., 2017; Goffena et al., 2018). Recent efforts have been made to fully define the underlying neuropathology and the molecular mechanism behind ELP2 pathogenic variants in patients with NDDs (Kojic et al., 2021). Although we have previously investigated the role of the Elp6 gene in neurological disorders in mice (Kojic et al., 2018), no clinically relevant patient-derived pathogenic variants in the accessory Elp456 subcomplex have been modeled and studied in vitro or in vivo, yet. Thus, it remains unclear whether this subcomplex plays a role for the central nervous system (CNS) development and associated pathologies.

In this work, we provide the clinical and molecular evidence for the direct involvement of ELP456 in NDDs by identifying a patient with ELP4 and two patients with ELP6 variants presenting with a range of severe neurodevelopmental defects. We demonstrate that these variants decrease the stability of the subcomplex, impair the activity of the Elongator complex, and are sufficient to recapitulate the clinical phenotype in mice. Foremost, our comprehensive study of the clinically relevant Elongator mutations reveals yet unrecognized differences of the Elongator subcomplexes in epitranscriptomic processes in neuronal subtype, both leading to profound but distinguishable CNS defects in model systems.

Results

**ELP4/6 pathogenic variants cause a complex neurodevelopmental phenotype**

During routine clinical examination, we identified one individual with two missense variants in ELP4 and two individuals with a missense variant in ELP6 presenting with a global developmental delay and dysmorphic features (Table 1 and Fig 1A). Other prominent clinical features consisted of ID, seizures, and motor dysfunction. Further examination revealed muscle spasm, hypotonia, lack of language, feeding difficulties, and inability to walk. Brain magnetic resonance imaging (MRI) showed microcephaly with cerebral and cerebellar atrophy and a thin corpus callosum indicating myelination defects or axon deficits (Table 1 and Fig 1B). Electroencephalography (EEG) detected abnormal background activity and generalized seizures (Table 1 and Figs 1C and, EV1A and B). ELP4 and ELP6 variants were identified by whole-exome sequencing. The affected individuals harbored either compound heterozygous missense variants in ELP4, ELP4Y91C/L296I, or homozygous missense variant in ELP6, ELP6L118W/L118W. Healthy parents were heterozygous carriers for the identified variants (Fig EV1C and D). Subsequently, we set out to establish a complete biochemical characterization of the murine and human Elp456 subcomplexes to further understand the direct consequences of the variants on Elongator complex function.

**Mammalian Elp456 subcomplexes form hetero-hexameric rings**

In yeast, the Elp456 subcomplex (yElp456) forms a hetero-hexameric ring which promotes ATP hydrolysis and release of tRNA during crucial steps of Elongator’s reaction cycle (Glatt et al., 2012). We employed the BigBac system (Weissmann et al., 2016) to simultaneously produce all three subunits of full length human (hElp456) and murine (mElp456) complexes in insect cells. Consequently, we obtained pure, homogenous, and stoichiometric samples of both mammalian subcomplexes (Fig EV2A). The complexes eluted at an
estimated molecular weight of ~220 kDa, showing no signs of proteolytic cleavage. Hence, hElp456 and mElp456 form a heterohexameric ring harboring two copies of each of the three subunits, like yElp456 (Fig EV2B). Next, we vitrified the purified samples for cryo-EM single particle analyses (SPA). After particle picking, iterative rounds of 2D and 3D classification and refinement, the obtained datasets resulted in maps of hElp456 at a resolution of 4.32 Å (EMD-14626) and mElp456 at a resolution of 4.03 Å (EMD-14627) (Fig 2A; Appendix Fig S1; Appendix Table S2). Our reconstructions have been complicated by a preferred orientation of the ring/disc shape of the Elp456 molecules, which despite various experimental approaches (e.g., addition of various detergents, tilted data collections) could not be circumvented. Based on the known crystal structure of yeast Elp456 (Glatt et al., 2012) (PDB 4a8j), we generated

---

### Table 1. Clinical features of patients carrying disease-causing ELP4 and ELP6 variants.

<table>
<thead>
<tr>
<th>Patient 1</th>
<th>Patient 2</th>
<th>Patient 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex, age</td>
<td>Female, 8 y, 9 m</td>
<td>Female, 20 y</td>
</tr>
<tr>
<td>Prenatal/neonatal course</td>
<td>Uncomplicated/hypotonia in the neonatal period</td>
<td>Uncomplicated</td>
</tr>
<tr>
<td>Developmental delay</td>
<td>Severe</td>
<td>Severe</td>
</tr>
<tr>
<td>Intellectual disability</td>
<td>Severe</td>
<td>Severe</td>
</tr>
<tr>
<td>Age of sitting/walking</td>
<td>Never achieved</td>
<td>Never achieved</td>
</tr>
<tr>
<td>Language abilities</td>
<td>Non-verbal</td>
<td>Non-verbal</td>
</tr>
<tr>
<td>Use of hands</td>
<td>No purposeful movements</td>
<td>No purposeful movements</td>
</tr>
<tr>
<td>Behavior/ASD</td>
<td>Cries for needs</td>
<td>No evidence available</td>
</tr>
<tr>
<td>Feeding difficulty</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Neurological exam</td>
<td>Generalized hypotonia, increased muscle tone in right arm, decreased reflexes in lower extremities; reflexes 3+ UE and 4+ knee jerk with clonus and ankle jerk with 4+ reflexes and clonus</td>
<td>Spastic tetraparesis, hyperactive deep tendon reflexes</td>
</tr>
<tr>
<td>Ophthalmological features</td>
<td>Cortical vision impairment bilaterally</td>
<td>Normal vision</td>
</tr>
<tr>
<td>Epilepsy</td>
<td>History of infantile spasms, first seizure at 5 m/Type A: tonic clonic; Type B: bilateral arm extension, unsure if seizure activity, limbs jerking and screams involuntarily</td>
<td>1 y, 6 m/myoclonic</td>
</tr>
<tr>
<td>Age of onset/seizure type</td>
<td>Poorly organized background, frequent multifocal independent spike foci, poorly organized sleep features</td>
<td>Background rhythm in the first EEG found to be slowed by age. Bilateral fronto-central-frontotemporal and left hemisphere centroparietal-parietooccipital regions were found to have phase encounters, spike-polyspike slow wave activities and generalization of these activities followed by electrocerecremental response detected in the last EEG.</td>
</tr>
<tr>
<td>EEG</td>
<td>Enlarged extra-axial CSF spaces and interfoliate sulci in keeping with cerebral and cerebellar volume loss, microcephaly</td>
<td>Thin corpus callosum, cerebral and cerebellar atrophy, microcephaly</td>
</tr>
<tr>
<td>AED received</td>
<td>Levetiracetam, CBD oil</td>
<td>Phenytoin, levetiracetam</td>
</tr>
<tr>
<td>Seizure frequency</td>
<td>Type A: once in 3–4 days, Type B: once a week</td>
<td>Unknown</td>
</tr>
<tr>
<td>Brain MRI</td>
<td>Scoliosis, hip dislocation bilaterally, congenital portosystemic shunt incidentally seen on abdominal US, ankle contractures</td>
<td>Low set ears, scoliosis, thin long fingers, overriding toes</td>
</tr>
</tbody>
</table>

AED, antiepileptic drugs; ASD, autism spectrum disorder; CBD, cannabidiol; CSF, cerebrospinal fluid; EEG, electroencephalography; m, months; MRI, magnetic resonance imaging; UE, upper extremities; y, years.
atomic models (Bertoni et al., 2017) of both human and murine Elp456 subcomplexes (Fig 2A). Despite the limited resolution and the reduced quality of the maps caused by the orientational bias, the models fit unambiguously into the densities, confirming the relative arrangement of subunits in mammals, and creating dimers of trimers with one rather flat and one rather uneven side of the ring (Fig 2A). Due to intrinsic flexibility, we were not able to identify additional densities for the N-terminus of Elp4 and the predicted C-terminal domain of Elp5. The high structural similarity of yeast, murine, and human Elp456 indicates a functional conservation of the subcomplex across eukaryotes.

**Elp4 and Elp6 mutations affect tRNA binding**

Next, we performed *in vitro* analyses of purified mElp456 complexes to assess the molecular consequences of the single amino acid substitutions found in the affected patients. Based on the high amino acid sequence conservation among the eukaryotic Elp4, Elp5, and Elp6 proteins (Fig EV2C), we were able to precisely locate the individual patient-derived mutations in the obtained atomic models of human and murine Elp456 subcomplexes (Fig 2A and B). The human variants *ELP4Y91C* and *ELP4L296I* correspond to murine Elp4Y90C/L294I and are positioned in unstructured flexible loop regions located at the interface between Elp4 and Elp5 subunits (Y91C mutation) and Elp4 and Elp6 subunits (L296I mutation; Fig 2A and B). The *Elp6L118W* substitution is found in the α-helix of the solvent exposed domain of Elp6 (Fig 2B). Notably, the previously described Elp6 mutation, *Elp6L126Q*, that causes an ataxia-like phenotype in *wobbly* mice (Kojic et al., 2018) is located within the same conserved region of the α-helix, which likely represents a crucial hotspot for the stability of the Elp456 subcomplex. To define molecular consequences of the patient-derived mutations, we

---

**Figure 1. Clinical information of the patients with neurodevelopmental disorders and identified ELP4/6 variants.**

A Anterior and lateral photographs of two patients with ELP6 variants showing dysmorphic features at 20 (Patient 2) and 19 (Patient 3) years of age.

B Mid-sagittal (I), coronal (II) and transversal (III) MRI scans of Patient 1 with newly identified ELP4 variants and Patient 2 and Patient 3 with ELP6 variants. Atrophy of the cerebellum with prominence of the cerebellar folia is marked by circles. Arrows indicate thin corpus callosum, red arrowheads point to enlarged extra-axial CSF spaces, and black arrowheads to cerebral sulci in keeping with cerebral and cerebellar volume loss.

C EEG of Patient 3. Left panel: 1–2 Hz left fronto-temporal spike and multi-spike slow wave discharges (Fp1-F7 and T3-T5) spread to the homologous same hemisphere and opposite hemisphere, predominantly seen on bipolar montage EEG. Right panel: Spike- and multi-spike slow wave activities together with fast rhythms originating from bilateral fronto-temporal-frontocentral regions indicate electrographic seizure activity. Described changes are marked by circles.
Figure 2.
introduced the substitutions into the murine Elp456 to obtain mElp4L294I, mElp456_118W, and mElp456_126I variants. We managed to purify all variants and subsequently compared their temperature-dependent unfolding rates to the wild-type Elp456 (mElp456WT; Fig EV2D). Although none of the mutations lead to a complete disassembly of the subcomplex in vitro, all Elp456 variants, apart from Elp4L294I, displayed a lower thermal stability profile than the wild-type Elp456. Strikingly, the Elp6L118W induced a significant destabilization of the mElp456 ring, as observed by a high fluorescent signal already at low temperatures. In summary, we show that the patient-derived Elp4 and Elp6 variants lead to decreased stability of the isolated murine Elp456 subcomplex.

Next, we tested the affinity of the purified mElp456 variants for in vitro-transcribed and fluorescently labeled murine tRNA^Ala^UGC and tRNA^Ala^mUCU carrying the Elongator-modifiable uridine at position 34 (U34; Fig 2C). Using microscale thermophoresis (MST), we observed a noticeable reduction in tRNA binding affinity toward tRNA^Ala^UGC for all tested Elp456 variants up to a three-fold affinity decrease for the Elp4L294I56 variant (K_d = 361 ± 31 nM; Fig 2C) in comparison to the Elp456WT (K_d = 123 ± 9 nM; Fig 2C). We initially suspected that the reduced thermostability directly leads to the reduced recognition of tRNA molecules. However, we did not observe such a strong correlation between thermostability and the reduction of affinity for the mouse arginine tRNA^UCU^, which is bound by all Elp456 complexes with a lower, but rather similar affinity (K_d between 440 and 600 nM). Our results indicate a selective effect of the identified variants in Elp456 subcomplexes toward specific tRNAs species, which can only partially be attributed to the observed decreased thermostability of the complex in vitro.

**ELP4 and ELP6 variants impair the function of the Elongator complex**

Elp456 is a component of the Elongator complex and was proposed to act as an ATP-driven tRNA release factor (Glatt et al., 2012). Hence, the decreased stability of Elp456 subcomplexes may indirectly affect the integrity and function of other Elongator subunits and the holoElongator complex (Fig 3A). First, we investigated the impact of the individual mutations on the assembly with the Elp123 subcomplex. We successfully reconstituted the wild-type complex (Elp123456WT) and four variants of the mElp456 subcomplexes in vitro via gel filtration co-migration analyses (Fig 3B). The stoichiometric interaction of all six Elongator subunits was independently confirmed using pull-down experiments (Fig 3C). Furthermore, we used co-immuno-precipitation analyses (Co-IP) to confirm that the two subcomplexes still assemble in fibroblasts derived directly from the patients (Fig 3D). We also found that the expression of its subunits is not affected by the mutations (Appendix Fig S2A). Our results show that all identified single amino acid substitutions in Elp4 and Elp6 proteins do not negatively influence the expression and interaction of the Elp123 and Elp456 subcomplexes and do not impede the assembly of the holoElongator complex at body temperature (37°C).

The active site of Elp3 around its 4Fe4S cluster (Fig 3A) is spatially rather distant from Elp456 or the identified amino acid substitutions in Elp4 and Elp6. We nevertheless asked whether the Elp4 and Elp6 variants (Fig 3B) influence the tRNA-induced acetyl-CoA (ACO) hydrolytic activity of the Elp3. We purified sufficient quantities of the reconstituted complexes and tested them in previously established ACO hydrolysis assays (Lin et al., 2019; Kojic et al., 2021). Strikingly, all four tested mutants showed a slight decrease in tRNA-independent basal activity and a complete inhibition of the tRNA-induced ACO hydrolysis in comparison to Elp123456WT (Fig 3E). These results demonstrate that the identified patient-derived mutations do not prevent the assembly of the Elongator complex, but instead have a detrimental effect on the ability of mElp123 to induce the initial step of the cm^2 modification reaction in vitro.

Furthermore, we investigated the impact of the ELP4 and ELP6 variants on the activity and function of the complex in vivo by analyzing tRNA modification levels in mouse-derived fibroblasts. Both cm^3U-dependent modifications, ncm^3U and mcm^3U, together with further modified mcm^5s^3U, were found to be significantly reduced in the cells originating from ELP4Y91C/L296D and ELP6L118W patients (Fig 4A–C), while Elongator-independent tRNA modifications were unaffected (Fig 4D and E). Hence, our data confirm that the patient-derived mutations in ELP4 and ELP6 not only diminish Elongator activity in vitro, but also impair tRNA modification in human cells.

To further assess the consequences of the reduced U34 modification levels on the respective cellular proteomes, we analyzed total protein extracts from the patient fibroblasts using nano-high performance liquid chromatography (HPLC) tandem mass spectrometry (MS). The analyses revealed altered protein expression levels in the patient cell lines (Fig 4F). As the decoding of only a specific subset of codons is affected by the U34 modifications, we have checked for any possible codon bias in the respective mRNA sequences of the mis-regulated proteins. We have found a preference for certain codons in the respective pools of up- and down-regulated proteins (Appendix Fig S2B). Though, no direct correlation between the modification-dependent codons and expression levels was observed.

A network-based clustering of cellular functions associated with the differentially expressed proteins showed an enrichment of

---

**Figure 2.** Mammalian Elp456 subcomplexes form tRNA binding assemblies that are affected by ELP4/6 mutations.

A Cryo-EM analyses of the reconstituted mammalian Elp456 (human—Elp456 and murine—mElp456) complexes. Reference-free 2D class averages of the human (top) and murine (bottom) Elp456 subcomplexes (left panels, scale bar 100 Å), cryo-EM maps (middle panels, scale bar 10 Å) and atomic models fit into the cryo-EM density maps with marked localization of patient-derived ELP4 and ELP6 mutations (right panels).

B Close-up view of Elp456 atomic models highlighting the positions of the Elp6 (L126—red and L126—brown) and Elp4 (L296/L294—magenta and Y91/Y90—violet) mutations. Elp4 is depicted in green, Elp5 in blue and Elp6 in brown. Mutations are marked on the respective sequence alignments of Elp6 and Elp4 with color-coded arrows.

C Microscale thermophoresis (MST) analysis of Elp456WT and Elp456 variant binding to murine (Mm—Mus musculus) tRNA^Ala^UGC (top) or Mm tRNA^Ala^mUCU (bottom) with estimated dissociation constant values (K_d) and K_d fitting errors (mean ± SD), n = 3 independent measurements.
pathways involved in translational regulation, RNA-related processes, and cytoskeleton organization (Fig 4G and H). Given that cytoskeleton is being affected by the variants and the previous studies showing that LOF of Elongator subunits can lead to defects in cell migration (Crepe et al., 2009; Close et al., 2012), we have tested the patient-derived fibroblasts in a wound healing assay. After inhibition of proliferation by mitomycin C, we were not able to detect any difference between control fibroblasts and the cells carrying the mutations in ELP4 or ELP6 (Appendix Fig S2C). Of note, the functional clusters that appear predominantly perturbed are similar for the ELP4 and ELP6 variants. Our data confirm that the respective patient-derived single amino acid substitutions in the ELP456 subcomplex impact on the proteomic landscape of human cells. Even though for technical reasons our analysis had to focus on
patient-derived fibroblasts, the observed changes on the molecular level confirm the direct link between the variants and noticeable differences in the proteomic signatures of human cells.

**Modeling Elp6L118W in mice recapitulates phenotypic features of the patients**

To address potential functional consequences that ELp6L118W has on brain development, we used CRISPR-Cas9 gene editing to introduce the mutation in mice. In contrast to the Elp2 mutant mice (Kojic et al., 2021) and similar to previously reported Elp6 mutants (Elp6L126Q; wobbly mice) (Kojic et al., 2018), neither global developmental delay nor microcephaly was observed in Elp6L118W animals based on body size and brain weight measurements (Figs 5A and EV3A and B). The animals presented with reduced weight likely due to their high susceptibility to neurodegeneration and disease (Anand et al., 2012). While no morphological changes in the cortical neurons (Fig EV4B–E) and to their high susceptibility to neurodegeneration and disease (Anand & Dhikav, 2012; Till et al., 2012). While no morphological changes were found in the cortical neurons (Fig EV4B–E), the analysis of stained hippocampal pyramidal neurons showed a significant reduction in both the length (Fig 6B and C) and branching (Fig 6D) of the dendrites in the Elp6 mutant animals, with no alternations in the dentritic spine density (Fig 6E).

**Hippocampal defects and neurodegeneration in Elp6L118W mice**

To identify brain structures affected by the mutation driving the severe phenotype of the Elp6L118W animals, we performed detailed histological analyses at postnatal (P) day 60. The analyses confirmed that no microcephaly was evident, with no significant changes found in the cerebral cortex or hippocampus of the mutant mice (Appendix Fig S3A–C). Similar to our previous findings in the Elp2 and Elp6 mutants (Kojic et al., 2018, 2021), widespread Purkinje neuron (PN) degeneration was observed in the cerebella of Elp6L118W animals (Appendix Fig S3D).

Next, we screened for potential neurogenesis defects in the cortical and hippocampal structures by performing Golgi-Cox staining to assess neuronal architecture. Pyramidal neurons of the II and III layers of the somatosensory cortex (Fig EV4A) and CA1 pyramidal neurons in the hippocampus were selected for analysis (Fig 6A) due to their high susceptibility to neurodegeneration and disease (Anand & Dhikav, 2012; Till et al., 2012). While no morphological changes were found in the cortical neurons (Fig EV4B–E), the analysis of stained hippocampal pyramidal neurons showed a significant reduction in both the length (Fig 6B and C) and branching (Fig 6D) of the dendrites in the Elp6 mutant animals, with no alternations in the dentritic spine density (Fig 6E).

To further explore functional consequences of the morphological abnormalities found in the hippocampal neurons, we investigated synaptic transmission at the Schaffer collateral to CA1 pyramidal neuron synapse. Schaffer collaterals were electrically stimulated, and field excitatory postsynaptic potential (fEPSP), which reflects a summation of excitatory postsynaptic responses, was recorded after applying high-frequency stimulation (HFS) to trigger long-term potentiation (LTP). Remarkably, reduced fEPSP was recorded in Elp6L118W mice relative to littermate controls (Fig 6F–H), suggesting defects in basal synaptic transmission affecting their learning abilities and memory (Gruart et al., 2006; Whitlock et al., 2006).

Immunofluorescence-based histological analysis was performed to analyze interneurons given their essential role in memory and cognition (Kirkcaldie, 2012), and previously identified interneuron defects in Elongator mouse models (Crepe et al., 2009; Tielen et al., 2016; Kojic et al., 2021). Interneurons were found not to be affected in the Elp6 mutants (Appendix Fig S4A and B). In addition, we screened for potential myelination impairment in the mutant
Figure 4.
Compromised activity of the Elongator complex in Elp6L118W mice

PN degeneration in Elp6L118W mice was found to occur in a more progressive manner than in the wobbly mice, with the Elp6L118W cerebellum being almost fully depleted of PNs by P60 whereas the wobbly mice lose half of the PNs by this age (Kojic et al., 2018) (Appendix Fig S5A). We sought to explore the cause of PN degeneration and whether unfolded protein response (UPR) is a prominent feature of these neurons and the cause of their death as previously identified in the Elp2 (Kojic et al., 2021) and Elp6 (Kojic et al., 2018) mutant mice. Indeed, we found UPR and ER-stress-mediated apoptosis to be a mode of PN death in these animals (Appendix Fig S5B-D). As we did not find evident microcephaly and cortical defects in the Elp6 mutants, we hypothesized that UPR was limited to the PNs. To test this, we analyzed the expression of one of the main transcriptional effectors of UPR, activating transcription factor 4 (Atf-4), previously linked to neurogenesis defects in the murine Elp3-depleted cortical neurons (Laguesse et al., 2015). Indeed, UPR was not evident in the cerebral cortex of the Elp6L118W animals (Appendix Fig S6A). Moreover, we found that ATF-4 expression was not affected in the patient fibroblasts as well (Appendix Fig S6B).

To assess the molecular consequences of the mutation behind the neuropathology in mice, we performed biochemical analyses of the murine brain tissue. Western blot analysis revealed that the mutation impaired the expression of the Elp6 protein, while other Elongator subunits seemed to be unaffected (Appendix Fig S6C), which is in agreement with our in vitro data. Consistent with our findings in the human cells, we detected reduced levels of Elongator-dependent tRNA modifications in the Elp6L118W brains (Fig EV5A–E). The modification of tRNA is reduced to a higher extent in the Elp6L118W than wobbly mice (Fig EV5F), further confirming the more detrimental effect of the clinically relevant mutation on the function of the holoElongator complex.

Discussion

Elongator functions as a fundamental translational regulator via modifying U44 in tRNAs and has been implicated in a wide range of neurodevelopmental activities (Kojic & Wainwright, 2016). Pathogenic variants in Elongator subunits have been associated with a spectrum of NDDs, but existing functional studies address almost exclusively variants in the catalytic ELP123 subcomplex. This study explores instances of clinical pathogenic variants in the accessory ELP456 subcomplex modeled in vitro and in mice, correlating clinical observation with the molecular impact of the variants on the function of the complex in maintaining proper tRNA modification levels.

In yeast, deletion of any of the six Elongator subunits leads to identical phenotypes and loss of Elongator-dependent tRNA modifications (Huang et al., 2005), which can be rescued by the overexpression of specific modified tRNA species (Esberg et al., 2006). Studies in mammals predominantly focused on the role of the enzymatically active Elp3 subunit. Our work on clinically derived ELP4/6 variants finally permits a fair and direct comparison between Elp123 and Elp456 variants and their role in neurodevelopment and disease. Strikingly, our study shows that in contrast to unicellular yeast, the two subcomplexes in higher eukaryotes presumably fulfill cell-type specific functions.

Although the patients with newly identified ELp4 and ELp6 pathogenic variants have common clinical features and brain MRI findings with recently reported patients with ELp2 pathogenic variants (Kojic et al., 2021), modeling the variants in mice revealed that different neuropathology drives the disease. PN degeneration is consistently found across different Elongator mutations (Kojic et al., 2018, 2021). However, in contrast to Elp2 mutant animals, no signs of microcephaly and no defects in myelination and development of cortical projection neurons and interneurons have been identified in Elp6L118W mice. Synapse dysfunction, branching, and dendritic length abnormalities, found in the hippocampal neurons of the
Figure 5. Physical presentation and motor defects in Elp6L118W mice.

A Appearance and quantification of body size and weight of adult (2-months-old) heterozygous and homozygous Elp6L118W mice and littermate controls (n = 8 animals per genotype).

B Abnormal hindlimb clasping of Elp6L118W animals. n = 6 for wild-type and Elp6L118W mice; n = 7 for Elp6L118W/+ animals.

C Significant effects of the Elp6 mutation on scores for behavioral tests, including body position, spontaneous activity, tremor, ledge test, and grip strength tests. n = 6 for wild-type and Elp6L118W mice; n = 7 for Elp6L118W/+ animals.

D Kaplan–Meier curve of mouse survival (n = 12 per genotype).

Data information: Statistical analysis: one-way ANOVA (a = 0.05) with a Dunnett’s post-hoc test. Statistically significant differences are indicated (*P ≤ 0.05; ***P ≤ 0.001; ****P ≤ 0.0001; ns—not significant). Data represent mean ± SEM.
Elongator mutants. In summary, although mutations in the Elp123 are known to affect the neuronal activity across different brain regions, the Elp456 ring is almost completely dispensable for some of these neurons. Nonetheless, Elp456 appears to be crucially important for pyramidal and Purkinje neurons in the hippocampus and cerebellum, respectively.

Hence, mutations in two subcomplexes may differently affect the brain cells, with those in the hexameric ring being less detrimental for the brain development than the mutations in the catalytic subcomplex. Neurons are known to be vulnerable to the accumulation of misfolded proteins and perturbation in the cellular activities shown to be driven by Elongator mutations (Kojic & Wainwright, 2016). PNs and hippocampal neurons are particularly sensitive to different kinds of physiological stress due to their enhanced metabolic demand relative to other neurons (Jiang et al., 2004; Kagias et al., 2012; Shetty et al., 2012; Lucas et al., 2015). Thus, perturbations in the Elp456 ring seem to be sufficient to cause defects in
these neurons, and any disruption in the catalytic Elp123 results in brain-wide impairment.

Our complementary in vitro analyses aim to resolve the role of Elp456 in higher eukaryotes and provide first molecular explanations for the observed differences between Elp123 and Elp456. Our biochemical experiments using purified mouse Elp456 show that mutations in Elp456 affect the binding to certain tRNA molecules, whereas the same mutations seem to have a much smaller impact on the interaction with other modifiable tRNAs. We speculate that these differences might be linked to the varying impact of the mutations on specific neuronal cell types. If tRNAs affected by mutations in Elp456 are not produced in certain cell types, the effect of the mutations might simply be irrelevant. Hence, it would also be of high interest to correlate our observations with cell-type specific tRNA iso-decoder expression data in vivo once reliable data on neuronal subtypes becomes available in the future.

While clinically relevant mutations found in the Elp123 subcomplex reduced the ACO hydrolysis activity of Elp123 by ~40%, Elp456 mutations almost completely abolish this activity in vitro. This observation is consistent with an almost complete absence of Elongator-dependent modifications in the tested patient-derived fibroblasts carrying ELP4/6 pathogenic variants. We speculate that disease relevant mutations in Elp123 need to permit a moderate activity level of Elongator, because residual tRNA modification levels are required for development and survival. Stronger mutations or disintegration of Elp123 would lead to lethality, as shown for deletions of Elongator genes in mice (Chen et al., 2009; Bento-Abreu et al., 2018; Kojic et al., 2018, 2021). Disease-associated mutations in Elp456 may still support the assembly of the complex at physiologically relevant temperatures, but lead to a greater reduction of activity, because its action is required only for a subtraction of neuronal cell types during development.

Consistent with studies of the catalytic subcomplex in model organisms (Laguesse et al., 2015; Nedialkova & Leidel, 2015; Kojic et al., 2021), ELP4/6 pathogenic variants perturb the integrity of the human proteome. The proteomic analyses and functional association identified the perturbation of cytoskeleton organization pathways, which could directly account for morphological defects of the hippocampal neurons. Of note, fibroblasts are fast-dividing cells and thus are more likely to tolerate alternations in translation and biosynthetic pathways. Hence, the patient-derived fibroblasts also showed no observable differences in cell migration. In contrast, similar changes in neurons might lead to more severe consequences, which could explain why they are particularly vulnerable to the detected pathogenic variants. Yet, the selective vulnerability of hippocampal over cortical neurons to these alternations remains elusive. We currently believe that these changes most likely occur due to tRNA selectivity as well as cell-type specific codon usage and the altered expression of specific key proteins. Foremost, the changes of the proteomic signatures confirm that patient-derived cell lines change their proteomic landscape, which we can directly link to the reduced activity of the Elongator complex and the change of tRNA modification patterns.

In summary, our study characterizes clinically relevant mutations in the accessory Elongator subcomplex in vitro and in vivo. Our results further highlight the crucial role of the complex in the emerging neuroeptitranscriptome (Shaflik et al., 2021) that drives development and maintenance of the CNS. We provide a direct link between defective Elp456, compromised function of the complex, and a complex neurological phenotype and reveal unanticipated differences between the two subcomplexes in the brain. Further studies of different neuronal types and their specialized proteomes in Elongator mutants will be essential to decipher these findings also on the molecular level.

**Materials and Methods**

**Clinical data collection**

The study was approved by the Research Ethics Board at The Hospital for Sick Children (project license number 1000070283) and the Dokuz Eylül University Clinical Research Ethics Committee (project license number 490-SBKAEK 2019/14-05). Patients with the compound heterozygous variants in ELP4 and the homozygous variant in ELP6 were recruited from the clinical research programs in Canada and Turkey, respectively. All patients were clinically evaluated by pediatric neurologists and medical geneticists at their respective healthcare centers. Clinical data were collected from the electronic patient charts using standardized questionnaires and interviews with patients and their parents. Brain MRI images were reviewed by a neurologist and a neuroradiologist. Parents provided written informed consent for publication of clinical pictures. Written informed consent was obtained from all subjects and the experiments conformed to the principles set out in the WMA Declaration of Helsinki and the Department of Health and Human Services Belmont Report. Patients underwent skin biopsies as a part of their clinical diagnostic investigations and their previously banked cultured skin fibroblasts were obtained for functional analysis. Fibroblast analyses were approved by the University of Queensland Institutional Human Research Ethics Committee (project license number 2020000858).

**DNA constructs**

Genes encoding ELP4, ELP5, and ELP6 from Homo sapiens (hELP456) and Mus musculus (mELP456) were cloned into pFastBac1 HTa plasmids with Flag-TEV-ProteinA tag sequence localized on the 3’ side of ELP6 genes. ELP123 and ELP456 constructs were generated using Gibson assembly method. In detail, ELP1 genes were cloned into pFastBac1, ELP2 into pFastBac1 HTa with the 6 x His tag sequence, and ELP3 into pFastBac1 with additional Twin-Strep-tag sequence on the 3’ side of the gene and assembled into plBiol1 expression vector. ELP4, ELP5, and ELP6 genes were assembled into pBiol1 expression vector. All six genes were amplified in PCR with primers adding overhangs on 5’ and 3’ sides of each gene and then assembled within pBigIa or pBigIb plasmids using standard protocol and primers (Weissmann et al., 2016). Mutations in mELP4 and mELP6 were introduced by QuickChange mutagenesis. A list of primers used for cloning and mutagenesis is provided in Appendix Table S1. All genetic constructs were moved to insect cells using standard Bac-to-Bac protocols.

**Recombinant protein production and purification**

For Elp456 protein expression, Hi-5 cells were infected with MOI = 1 and grown for 3 days at 27°C on a shaking platform. The Elp123 subcomplex was expressed in the Sf9-1 cells. Subsequently,
insect cells were lysed in Lysis Buffer (for Elp456: 50 mM HEPES pH 7.5, 150 mM NaCl, 2 mM MgCl₂, 2 mM DTT, 5% glycerol, DNase I, protease inhibitors; for Elp123: 50 mM HEPES pH 7.5, 100 mM NaCl, 2 mM DTT, 5% glycerol, DNase I, protease inhibitors) by 3 rounds of freezing and thawing in liquid nitrogen and sonication, followed by two-step centrifugation (4°C, 1 h, 80,000 × g). Elp456 supernatants were purified on IgG agarose beads (Merck) followed by overnight TEV cleavage in Cleavage Buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 2 mM MgCl₂, 2 mM DTT). On the next day, the protein sample was run on S200 Increase 10/300 GL column (GE Healthcare) in Final Buffer (20 mM HEPES pH 7.5, 100 mM NaCl, 2 mM MgCl₂, 5 mM DTT). Elp456 variants were purified using StrepTrap HP 5 ml column (GE Healthcare) eluted in Strep Elution Buffer (50 mM HEPES, 100 mM NaCl, 1 mM DTT, 5% Glycerol, 5 mM d-desthiobiotin, pH 8.0), followed by affinity chromatography on HiTrap Heparin HP 5 ml column (GE Healthcare) eluted in a gradient of Heparin Elution Buffer (50 mM HEPES, 1,000 mM KCl, 1mM DTT, pH 8.0). Lastly, eluates were run on Superose 6 Increase 10/300 GL column (GE Healthcare) in Final Buffer (20 mM HEPES pH 7.5, 100 mM NaCl, 5 mM DTT).

**Elp123456 reconstitution and in vitro pull-down**

The mElp123456 subcomplexes were incubated with the Elp456 variants for 30 min at 25°C in 2:1 ratio, followed by purification step on the Superose 6 Increase 10/300 GL column (GE Healthcare) in Final Buffer (20 mM HEPES pH 7.5, 100 mM NaCl, 5 mM DTT).  

For pull-down experiments, the mElp123456 subcomplexes were immobilized on the Dynabeads MyOne Streptavidin C1 (ThermoFischer) via Twin-Strep-tagged Elp3 protein, incubated with the Elp456 variants for 30 min at 4°C, washed 3 times in the Wash Buffer (20 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.05% Tween 20), and eluted from the beads in Elution Buffer (20 mM HEPES, 100 mM NaCl, 1 mM DTT, 5 mM d-desthiobiotin, pH 8.0). The inputs and pull-downs were loaded on the SDS-PAGE gels and visualized by Coomassie staining.

**Electron microscopy**

Purified Elp456 subcomplexes were applied to glow discharged carbon-coated cryo-EM grids (Quantifoil R 1.2/1.3 copper, 200 mesh). A total of 2.5 µl of sample (0.58 mg/ml) was plunge-frozen using FEI Vitrobot Mark IV set to 100% humidity and 4°C (blotting parameters: wait time: 15 s; blot force: 5 s; blot time, 8 s). Micrographs were acquired at 300 kV using FEI Titan Krios equipped with a Gatan Quantum energy filter and a K2 Summit direct detector. The graphs were acquired at 300 kV using FEI Titan Krios equipped with a Gatan Quantum energy filter and a K2 Summit direct detector. The graphs were prepared in Prism v8.0.2 (GraphPad) software.

**Image processing**

Frame alignment and dose weighting were performed with MotionCor2 (using Fourier space cropping by a factor of 2, resulting in a pixel size of 1.72), and contrast transfer function was determined with CTFIND4. Total number of 336,000 (mElp456) and 209,000 (hElp456) particles were template-based picking in Cryospar v3.2.0. Classification, refinement, post-processing, and local resolution estimation were performed with RELION3.1 and Cryospar v3.2.0. Particles were subjected to reference-free classification, from which 288,000 particles (86%) for mElp456 and 176,000 particles (84%) for hElp456 were selected for subsequent processing. Masked 3D classification was performed with the selected unbinned particles. Major classes containing more than 80% of particles were selected with recognizable Elp456 ring-like shape and refined. After post-processing, we obtained the mElp456 map with a resolution of 4.03 Å and 252,000 particles. For the hElp456 subcomplex, the classification and refinement yielded the map at a resolution of 4.32 Å. These maps were refined with C2 symmetry, applying a mask that covered the whole molecule. Cryo-EM maps were prepared using ChimeraX (Goddard et al, 2018; Pettersen et al, 2021).

**Structure modeling**

Elp4, Elp5, and Elp6 protein atomic models were predicted by homology to previously solved structure with SWISS-MODEL server (Bertoni et al, 2017). The mElp123456 structural model was created with SWISS-MODEL using yeast Elp123456 cryo-EM structure as a template (PDB). All models were made in PyMOLv2.1 (Schrödinger, 2018).

**Thermal shift assay**

Protein samples were concentrated to 2 g/l in 20 mM HEPES, 150 mM NaCl, 5 mM DTT, pH 7.5, and mixed with 25 µl SYPRO Orange (ThermoFisher) on a 96-well qPCR plate. CFX96 Real-Time System C1000 Touch Thermal Cycler (Bio-Rad) was used to gradually heat samples from 4 to 98°C with at heating rate of 0.2°C/10 s. The fluorescence intensity was measured at probe-specific excitation (470 nm) and emission (570 nm) wavelengths. The graphs were prepared in Prism v8.0.2 (GraphPad) software.

**Microscale thermophoresis for tRNA binding assay**

The internally Cy5-labeled murine (Mm—Mus musculus) tRNA<sup>Arg<sub>CUU</sub></sup> (0.2 µM) or Mm tRNA<sup>Ala<sub>UCG</sub></sup> (0.3 µM) were incubated with 16 serial dilutions of mElp456 variants (starting from 10 µM) in MST Buffer (20 mM HEPES, 100 mM NaCl, 5 mM DTT, pH 7.5, 0.0125% Tween 20). Measurements were performed at 60% excitation power in Premium Coated capillaries on the Monolith NT.115 (Nano temper Technologies) at 37°C. Obtained data were analyzed and dissociation constant values were calculated using MO. Affinity software (Nanotemper Technologies) from at least three independent experiments. The graphs were prepared in Prism v8.0.2 (GraphPad) software.

**Acetyl-CoA hydrolysis assay**

Each of the Elp123456 variants in concentration of 0.3 µM was mixed with 2 µM human bulk tRNA in presence of 100 µM acetyl-CoA in 1x acetyl-CoA assay buffer and incubated in a thermocycler for 3 h at 37°C. Next, the samples were passed through a 3 kDa cutoff concentrator (EMD Millipore). Flow-through was collected and pipetted into a 96-well plate. Acetyl-CoA quantity in each sample was determined with Acetyl-CoA Assay Kit (MAK039, Merck) according to the
manufacturer’s instructions. Fluorescence intensity was measured on a plate reader (TECAN) at probe-specific excitation (535 nm) and emission (587 nm) wavelengths. Hydrolysis rates were calculated from at least three independent experiments. The graphs were prepared in Prism v8.0.2 (GraphPad) software.

Cell culture

Fibroblasts from ELPA491C/L296L and ELPA6L118W patients and mother (ELPA6L118W/+ ) were obtained through punch biopsy, while control fibroblasts (TIG-102) were purchased from JCRB Cell Bank. Dulbecco’s Modified Eagle’s Medium (11995065, ThermoFisher) with 10% FBS (10099141, ThermoFisher) and added penicillin/Dulbecco’s Modified Eagle’s Medium (11995065, ThermoFisher) control fibroblasts (TIG-102) were purchased from JCRB Cell Bank. Protein was used. A lysate pre-clearing was performed using 20 µl of total protein (input samples) with 40 µg/ml mitomycin C to inhibit cell proliferation. Next, medium was removed and replaced with fresh one. After removal of the insert, image acquisition was performed under standard culture conditions (37°C, 5% CO2) using a Leica DMi6000B microscope (10x magnification). Pictures were collected every hour for a period of 24 h. Data analyses and quantification of the normalized wound area were done using Fiji ImageJ.

Wound healing scratch assay

A total of 35,000 cells per well were seeded in a 12-well plate with special inserts (Ibidi). One hour before analysis, cells were treated with 40 µg/ml mitomycin C to inhibit cell proliferation. Next, medium was removed and replaced with fresh one. After removal of the insert, image acquisition was performed under standard culture condition (37°C, 5% CO2) using a Leica DMi6000B microscope (10x magnification). Pictures were collected every hour for a period of 24 h. Data analyses and quantification of the normalized wound area were done using Fiji ImageJ.

Co-immunoprecipitation (Co-IP)

Confluent cells were collected from a 100 mm Petri dish, washed with ice-cold PBS, and lysed with 100 µl lysis buffer (0.5% TRITON X-100, 50 mM Tris/HCl pH 7.5, 1 mM EDTA, 150 mM NaCl, PMSF), sonicated and centrifuged for 10 min at 4°C (14,000 g). Overall protein concentration in the samples was determined by BCA Assay kit (ThermoFisher Scientific). For each IP experiment, 500 µg total protein was used. A lysate pre-clearing was performed using 20 µl protein A magnetic beads (Cell Signaling), incubated and rotated for 20 min at RT. Subsequently, the supernatant was collected from the beads and ELP1 antibody (Cell Signaling; #5071) was added at 1:50 dilution in a final volume of 200 µl and incubated at 4°C, overnight. Pre-washed protein A magnetic beads (20 µl) were mixed with lysate-ELP1 antibody, incubated by rotation for 20 min at RT. Next, beads were washed 3 times with the lysis buffer, resuspended in 15 µl 1x SB buffer, and boiled at 95°C for 5 min. Subsequently, samples were subjected to western blot analysis.

Western blot analysis (Co-IP samples and ATF-4 in human fibroblasts)

For SDS–PAGE electrophoresis, 15 µg total protein (input samples) and 25% of IP eluates were loaded on the gel. After the semi-dry transfer into 0.2 µm PVDF membrane, membranes were blocked for 1 h in 5% milk or 5% BSA. Primary antibodies used: anti-ELP1 (1:1,000 dilution; ThermoFisher Scientific; PA5-20286), anti-ELP3 (1:500 dilution; Cell Signaling; # 57285), anti-ELP4 (1:500 dilution; Biotechnne; NBP2-16322), anti-ELP5 (1:500 dilution; ThermoFisher Scientific; PA5-54745), anti-ATF4 (1:1,000; Abcom; ab184909); anti-α-tubulin (1:1,000; Sigma Aldrich; CP06). Membranes were incubated with primary antibodies at 4°C, overnight, followed by incubation with horseradish peroxidase-conjugated secondary antibodies (anti-mouse or anti-rabbit at 1:2,000 dilution for 1 h, RT). For detection, chemiluminescent substrate was used and membranes were developed on ChemiDoc XRS system (Bio-Rad).

Animals and genotyping

All experimental procedures conducted on mice were approved by the University of Queensland Molecular Biosciences Ethics Commit-tee (project license numbers IMB/125/19 and IMB/416/19). Mice were housed under standard conditions, a 12-h light/dark cycle with food and water available ad libitum, at ambient temperature (22 ± 2°C) with relative humidity (30–60%). Elp6L118W mice were generated using CRISPR/Cas9 on C57BL/6 genetic background.

Genomic DNA for genotyping purposes was obtained from toe clips using QuickExtract DNA extraction solution (Epicenter) as per manufacturer’s instructions. A custom TaqMan SNP genotyping assay (Applied Biosystems) was used to genotype the animals in a qPCR reaction based on allelic discrimination. Genotyping primers are included in Appendix Table S1. Cycling conditions used were 95°C for 10 min, followed by 40 cycles of denaturation at 92°C for 15 s and annealing and extension at 60°C for 1 min. The amplified product of 626 bp was further annealed with VIC-labeled wild-type or FAM-labeled Elp6L118W sequence (Appendix Table S1).

Behavioral testing

Animals were tested between P60 and P70 according to the modified SHIRPA screen (v1.04: 2002.3) (Rogers et al., 1997) and previously published simple composite phenotype scoring system for evaluating mouse models of spinocerebellar ataxia (Guyenet et al., 2010). All tests were repeated three times and scored as described below on a scale 0–3 (0–2 for tremor).

Body position: A mouse was placed in a cylindrical viewing jar (15 cm diameter) and observed for 2 min. Following scores were assigned.

A score of 0: The mouse is frequently rearing on hind legs.
A score of 1: The animal attempts to rear but is unable to do so as it loses balance.
A score of 2: Sitting or standing, no vertical activity (rearing) present.
A score of 3: Completely flat/laying on side.

Spontaneous activity: Mouse activity was recorded after spending 1 min in the viewing jar (allowing some time for the animal to accommodate). Following scores were assigned.

A score of 0: none, resting
A score of 1: casual scratch, groom, slow movement
A score of 2: vigorous, rapid/dart movement
A score of 3: extremely vigorous, rapid/dart movement
**Tremor:** Following scores were assigned to the animals in the viewing jar while recording their spontaneous activity.

A score of 0: no tremor  
A score of 1: mild tremor  
A score of 2: severe tremor

**Ledge test:** An animal was held by its tail on the cage ledge and observed as it walked along the ledge. Following scores were assigned.

A score of 0: The animal walks along the ledge without losing its balance. No tremor apparent and the walk is highly coordinated.  
A score of 1: The mouse loses its footing while walking along the ledge, and it appears like it struggles to walk.  
A score of 2: The mouse shows signs of tremor, loses its footing while walking along the ledge, and it appears like it struggles to walk.  
A score of 3: Severe tremor is present, and the mouse falls off the ledge, or nearly so or shakes and refuses to move at all despite encouragement.

**Hindlimb clasping:** An animal was lifted by the base of its tail and held clear from surroundings to observe the position of the hindlimbs for 30 s. Following scores were assigned.

A score of 0: The hindlimbs are consistently splayed outward, away from the abdomen.  
A score of 1: One hindlimb is retracted toward the abdomen for more than 50% of the time suspended.  
A score of 2: Both hindlimbs are partially retracted toward the abdomen for more than 50% of the time suspended.  
A score of 3: Hindlimbs of the mouse are entirely retracted and touching the abdomen for more than 50% of the time suspended.

**Grip strength:** A mouse was lifted by the tail and allowed to grip the wire of the animal cage with front paws. The animal is then gently pulled horizontally backward until it let go the wire. Following scores were assigned.

A score of 0: active grip, effective  
A score of 1: moderate grip, effective  
A score of 2: slight grip, semi-effective  
A score of 3: none

All behavioral analyses were performed by researchers blinded to the genotype of the animals.  

The graphs were prepared in Prism v9.0.1 (GraphPad) software.

**Tissue collection**

Experimental animals were anaesthetized using Ketamine (100 mg/kg; intraperitoneal injection) and Xylazine (10 mg/kg; intraperitoneal injection) prior to transcardial perfusion with phosphate-buffered saline (PBS), followed by 4% paraformaldehyde (PFA) solution. Dissected brain tissue was drop-fixed in 4% PFA at 4°C for 12 h under constant agitation. Next day, the tissue was washed three times in PBS and stored in 70% ethanol. For histological studies, brains were processed in an automated tissue processor over 15 h as per the user’s guide, subsequently embedded in paraffin and sectioned at 7 μm in the sagittal plain using microtome (Leica RM2235). Sections were transferred to glass slides and dried overnight at 37°C.

**H&E staining, imaging, and analyses**

Sections were deparaffinized with xylene and ethanol solutions of decreasing concentration prior to heat-induced antigen retrieval using a citrate buffer-based antigen unmasking solution (Abacus) for 10 min at 100°C. To prevent unspecific binding of antibodies, M.O.M. blocking reagent (Vector) was used for primary antibodies raised in mouse, and 4% horse serum (Life Technologies) for the antibodies raised in other species. Following primary antibodies were used: CC3 (1:50; ab2302), CHOP (1:100; ab11419), MBP (1:100; ab40390), Parvalbumin (1:200; ab11427), Pcp2 (1:100; sc-49072), and Ub (1:100; ab7780), followed by incubation with an AF488 or AF594-labeled donkey anti-mouse, anti-rabbit, or anti-goat antibody (1:250; Invitrogen) and counterstained with DAPI (Sigma Aldrich). Confocal images were taken using Olympus VS120 brightfield slide scanner. Cortical layer thickness and hippocampal length and width measurements were acquired using ImageJ software (Schneider et al., 2012). The area of measurements is indicated by dotted lines on the respective images. The graphs were prepared in Prism v9.0.1 (GraphPad) software.

**Immunofluorescence staining, imaging, and analyses**

Brain sections were deparaffinized and hydrated in a series of xylene and ethanol solutions of decreasing concentration prior to heat-induced antigen retrieval using a citrate buffer-based antigen unmasking solution (Abacus) for 10 min at 100°C. To prevent unspecific binding of antibodies, M.O.M. blocking reagent (Vector) was used for primary antibodies raised in mouse, and 4% horse serum (Life Technologies) for the antibodies raised in other species. Following primary antibodies were used: CC3 (1:50; ab2302), CHOP (1:100; ab11419), MBP (1:100; ab40390), Parvalbumin (1:200; ab11427), Pcp2 (1:100; sc-49072), and Ub (1:100; ab7780), followed by incubation with an AF488 or AF594-labeled donkey anti-mouse, anti-rabbit, or anti-goat antibody (1:250; Invitrogen) and counterstained with DAPI (Sigma Aldrich). Confocal images were taken using Olympus FV3000 and Zeiss LSM710 upright microscopes as Z-stacks and presented as a sum of the Z-projections. The images were further exported for processing and analysis in ImageJ (Schneider et al., 2012). Size of the sections on which cell number and mean pixel intensity quantifications were performed is specified in the figures. The graphs were prepared in Prism v9.0.1 (GraphPad) software.

**Golgi-Cox staining and neuron morphology analyses**

Animals were transcardially perfused at P60 using PBS followed by 0.04% PFA. Brains were dissected and stained using FD Rapid GolgiStain Kit (FD Neuro Technologies, Columbia, USA) per manufacturer’s instructions. The brains were sectioned in the coronal plain at 150 μm thickness in 30% sucrose using a vibramtome (Leica VT1000 S). Sections were imaged using Olympus BX63 upright microscope. Cortical pyramidal neurons from the II and III layers of the sensorimotor cortex and hippocampal pyramidal neurons from the CA1 region were selected for morphological analysis. Basal dendritic trees were reconstructed for Scholl analysis using Simple Neurite Tracer (Longair et al., 2011) in ImageJ software (Schneider et al., 2012). Clearly defined dendritic spines were quantified along 10 μm length of each
neuron’s secondary shaft. The graphs were prepared in Prism v9.0.1 (GraphPad) software.

Protein extraction and western blot analysis (murine samples and human fibroblasts)

Brain tissue was homogenized, and fibroblasts lysed in radioimmunoprecipitation assay (RIPA) buffer (150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 25 mM Tris pH 8), with protease inhibitors (Cell Signalling). Protein concentration was determined by BCA assay (Pierce). Total of 25 μg of protein lysate per sample was resolved on SDS-PAGE using NuPAGE 4–12% gels (NP0322PK), mini gel tank, and blot system (Life Technologies). Proteins were transferred onto polyvinylidene difluoride membrane (NP0322PK), mini gel tank, and blot system (Life Technologies). Proteins were transferred onto polyvinylidene difluoride membrane at 25 V for 90 min. The membrane was incubated for 1 h in 5% skimmed milk in TBS-T (10 mM Tris pH 8, 150 mM NaCl, 0.1% Tween 20) under constant agitation, washed twice in TBS-T, and incubated overnight at 4°C with antibodies against βIII-tubulin (1:10,000; ab78078), β-actin (1:10,000; ab8224), Atf-4 (1:1,000; ab1371), Elp1 (1:1,000; #5071), Elp2 (1:500; ab154643), Elp4 (1:500; NBPB2-16322), and Elp6 (1:500; orb53335). Next day, the membrane was washed in TBS-T three times for 15 min and incubated under constant agitation for 1 h at room temperature with relevant horseradish peroxidase-conjugated secondary antibodies (1:2,500; Abcam). Peroxidase activity was detected using SuperSignal West Pico chemiluminescent (Thermo Fisher Scientific) by ChemiDoc MP imaging system (Bio-Rad Laboratories). Densitometric analysis of western blot images was performed using ImageJ software (Schneider et al., 2012). The graphs were prepared in Prism v9.0.1 (GraphPad) software.

High-performance liquid chromatography (HPLC)/mass spectrometry (MS) protein analysis

The analysis of total protein lysates from human fibroblasts was performed as previously described (Kojic et al., 2021). First, in-gel destaining and trypsin digestion of proteins was performed. In short, 9 samples (ELP4 variants, ELP6 variants and controls; 3 technical repeats per genotype) were excised from each lane of the Coomassie blue-stained SDS–PAGE gel and placed into separate Eppendorf tubes (10 gel pieces per each lane/sample were obtained). Destaining of these samples was performed by adding 500 μl of 100 mM ammonium bicarbonate/acetonitrile (1:1; vol/vol) buffer and incubating the samples for 30 min. The buffer was replaced with 200 μl of acetonitrile in two separate batches. Upon removal of acetonitrile, the gel pieces were covered with 200 μl of sequence-grade trypsin of 20 ng/μl concentration in 50 mM ammonium bicarbonate pH 8 buffer (Promega Corporation) and incubated at 37°C overnight. Next day, 200 μl of 5% formic acid/acetonitrile (3:1; vol/vol) was added to the samples. The supernatant with the trypsin solution was transferred to a clean tube for each sample and dried in a vacuum centrifuge. Prior to high-performance liquid chromatography (HPLC) and mass spectrometry (MS) analysis, 12 μl of 1% (vol/vol) TFA in water was added to each tube, followed by centrifugation for 1 min at 12,000 g.

The tryptic peptide extracts were analyzed by nano-HPLC and MS on an Eksigent, Ekspekt nano LC400 HPLC (SCIEX, Canada) coupled to a Triple TOF 6600 mass spectrometer (SCIEX, Canada) with a micro DuolonSpray microflow ion source (SCIEX, Canada). 5 μl of each sample were injected onto a 5 mm × 300 μm, C18 3 μm trap column (SGE, Australia) for 6 min at 10 μl/min. This was followed by washing the trapped tryptic peptide extracts onto analytical 300 μm × 150 mm Zorbax 300SB C18 3.5 μm column (Agilent Technologies, USA) at 45°C and a 3 μl/min flow rate. For peptide elution, a linear gradient of 2–25% solvent B, 0.1% formic acid in acetonitrile, over 60 min at 3 μl/min was used, followed by 25–35% solvent B in 13 min, and then 35–80% solvent B in 2 min, then finally 80–90% solvent B for 5 min. Following each elution, the gradient was returned to 2% of 0.1% formic acid in acetonitrile for equilibration prior to injecting the next sample. The ionspray voltage was set to 5,500 V, declustering potential (DP) 80 V, curtain gas flow 25, nebuliser gas 1 (GS1) 15, heater gas (GS2) 30, interface heater at 150°C. 150 ms full-scan TOF-mass spectrometry (TOF-MS) data was acquired by the spectrometer, followed by up to 50 ms full-scan product ion data with a rolling collision energy and in an Information Dependent Acquisition (IDA) mode. The TOF-MS data were acquired over the mass range 350–1,800 and for product ion ms/ms 100–1,500. Ions in the TOF-MS scan that were found to exceed a 150 counts threshold and >2 to <5 charge state were set to trigger the acquisition of product ions.

Data were acquired under the same HPLC and MS experimental conditions, with the following exceptions. Data were acquired using a SWATH, product ion ms/ms all approach. The SWATH experiment was set to acquire 100 product ion spectra from m/z 350 to 1,500 per scan cycle with a product ion window was set to 6 Da and collision energy from 16 to 60 V with an energy spread of 5 V. The TOF-MS scan acquisition time was set to 50 ms and each product ion scan to 25 ms. The data were acquired and processed using Analyst TF 1.7 software (ABSCIEX, Canada). Protein identification and library compilation were carried out using Protein Pilot 5.0.2 for database searching. Peptide sequence identification and protein grouping were conducted by merging all individual IDA acquisition files from the gel fractions using the Paragon algorithm from Protein Pilot 5.0.2 against the Homo sapiens Uniprot database complemented by the contaminant sequences from thegpm.org/crap/ with the following parameters: Cys alkylation was set to iodoacetamide, Trypsin was chosen as digestion enzyme, Special Factors: Gel-based-ID was enabled to account for potential, ID Focus: Biological modifications, Thorough ID, ProtScore (Conf) > 10%, and False discovery analysis. The processing settings were set as follows for the peak area extraction in all SWATH acquisition using the local generated ion library: Number of peptides per Protein: 6, Number of Transitions per Peptides: 6, Peptide Confidence Threshold: 99%, < 1% FDR. Modified peptides were excluded for the protein quantitation and XIC extraction window: 15 min with a mass width of 50 ppm and retention times were aligned using a set of high intense Tryptsin autodigest peptides. The ion, peptide, and protein area were exported as a text file and the integrated area values for each protein that was present in different gel bands for each gel lane were summed before statistical evaluations, correlation of variation, and fold change computation. Normalization evaluations were done using the Normalyzer tool.

Proteomics data analysis

A total number of 2,730 peptides corresponding to 660 proteins were identified by DIA/SWATH-MS. Peptide-level intensities were
log2 transformed and normalized using the cyclic loess method. Peptides detected in less than four samples were removed and then missing values were imputed using msImpute R package (preprint: Hediyyeh-zadeh et al., 2020). Differential analysis of peptides was performed with limma package using linear models with empirical bayes moderation, where P-values were adjusted for multiple hypothesis testing using Benjamini-Hochberg method (Ritchie et al., 2015). Peptides with adjusted P-values < 0.05 were considered significant. Pathway enrichment was performed on gene sets obtained from MSigDB (Liberzon et al., 2011) in R using fgsea package (preprint: Korotkevich et al., 2021) by ranking peptides using their log-fold change. The significantly enriched pathways (adjusted P-value < 0.05) were subsequently clustered and visualized using vissE R package (Bhuva, 2021).

tRNA modification analysis

Total RNA was extracted from approximately 100 mg of brain tissue from P60 mice and homogenized with ceramic beads (Sapphire Bioscience) in a TRIzol reagent (Life Technologies) using tissue homogenizer (Bertin Technologies). Total RNA and tRNA extraction, tRNA hydrolysis to ribonucleosides, and tRNA modification analysis were performed as previously described (Kojic et al., 2018). HPLC coupled to MS was performed using a Luna Omega 1.6 μm, Polar-C18 100 Å column (150 mm × 2.1 mm, Phenomenex, Australia). Mass spectrometry parameters were determined for targeted ribonucleosides using multiple injections of 0.1–1 ng of purified ncm^3_U, ncm^3_U and ncm^3_U nucleosides (a generous gift from Sebastian Leidel, University of Bern, Switzerland) and commercially obtained m^7_G (Santa Cruz Biotechnology). The obtained retention times for these nucleosides were superimposed from the previously published results (Su et al., 2014) and the same used to obtain retention times for m^7_A and pseudouridine (Ψ). MultiQuant-v2.1.1 (ABSciei) software was used for peak assignment and quantification. Pseudouridine served as an internal normalization standard. The graphs were prepared in Prism v9.0.1 (GraphPad) software.

Hippocampal slice preparation for electrophysiology

Following anesthesia by sodium pentobarbital (60–80 mg/kg; intraperitoneal injection), whole brains were dissected out of the skull and submerged in a Mg^2+-high and sucrose-high artificial cerebrospinal fluid (aCSF; 87 mM NaCl, 2.5 mM KCl, 1.3 mM NaH2PO4, 7 mM MgCl2, 25 mM NaHCO3, 75 mM sucrose, 5 mM ascorbate and 0.5 mM CaCl2) made fresh on the day and frozen at –80°C for 30 min. The caudal end of the brain was fixed on a metal platform with a monocryacrylate glue with the ventral side supported by an agar block and submerged into ice-cold aCSF (as above) in a chamber. Coronal hippocampal sections of 300 μm thickness were made using a vibratome (Leica VT1200 S), approximately from bregma –1.58 mm to –2.70 mm. These slices were incubated in the same aCSF at 37°C for 40 min and then transferred into a new holding chamber with a Ca^2+-high and Mg^2+-low recording aCSF (130 mM NaCl, 26 mM NaHCO3, 3 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 1.25 mM NaH2PO4 and 10 mM D-glucose) at room temperature (20–22°C) for 30 min. All solutions were constantly bubbled with carbogen (95% O2 + 5% CO2) to maintain a pH of 7.4.

The paper explained

Problem

Brain development is a fundamental process driven by highly regulated genetic programs. Any disruption of essential neurodevelopmental processes results in neurodevelopmental disorders (NDDs) characterized by an inability to reach cognitive and motor milestones. NDDs affect more than 3% of children worldwide. High co-occurrence of different NDDs is indicative of shared etiology. Genome-wide analysis allows identification of associated genetic factors, but without detailed functional studies, the underlying cause and pathophysiology of certain groups of NDDs remain elusive.

Results

This study provides the first clinical evidence for missense mutations in the Elongator accessory subcomplex ELP456 to cause neurodevelopmental disorders. Pathogenic variants of ELP4 and ELP6 were identified in patients with severe clinical presentation of NDDs. Modeling the patient-derived mutations in mice recapitulated the complex neurodevelopmental phenotype and revealed neuron-specific consequences of the mutations. Reconstitution of the Elongator complex in vitro showed that the ELP4/6 variants affected its activity by decreasing tRNA modification levels in human and murine cells. Foremost, the obtained data reveal previously unrecognized differences between the ELP123 and ELP456 subcomplexes and their involvement in neuropathology.

Impact

The presented work provides a fundamental basis to understand the role of the Elongator complex in the development of neurons and brain structures. The findings highlight novel concepts for studying clinically relevant mutations in mouse models and provide a direct link between mutations in the ELP4/6, the compromised function of the complex and severe neurodevelopmental phenotypes.

Electrophysiological recordings and induction protocols

Individual hippocampal slices were transferred into a recording chamber (Kerr Scientific Instruments, NZ), held down with a platinum wire/nylon thread U-shaped mesh (10 mm × 8 mm), and continuously superfused with recording aCSF (1–3 ml/min) at 22°C throughout the experiment. Neurons from CA3 to CA1 region were visualized with a Nikon SMZ445 stereomicroscope. Extracellular field recordings in the CA1 stratum radiatum were obtained with a monopolar recording electrode and evoked by a bipolar stimulating electrode separated by approximately 3 mm. The fEPSP was evoked by brief electrical stimuli (0.1 ms, 0.1–2 mA) at 0.1 Hz for generating an Input-Output (I/O) curve and for baseline recordings, whereas 3 bursts of 100 Hz high-frequency stimulation for 1 s were used for LTP induction. Apart from LTP induction, fEPSPs were recorded at 10-second intervals throughout experiments.

An I/O curve was first generated to determine the stimulus strength used for each experiment, which was 50–60% of the stimulus strength resulting in the maximum fEPSP response. Following a 10-min baseline recording period where the fEPSP amplitude and initial slope were considered stable, LTP was induced by three separate bursts of high-frequency electrical stimulation (100 Hz with 100 stimuli for 1 s) at the Schaffer collaterals within 3 min. Post-LTP induction was subsequently recorded for 30 min at 0.1 Hz with an interval of 10 s. The stimulus was delivered via a stimulus
isolation (FE180, ADInstruments). Data were AC filtered and amplified (1–100 ×, Kerr Scientific Instruments S2 amplifier), digitally low-pass filtered (2 kHz cutoff), sampled at 10 kHz (Power lab, ADInstruments), and recorded and processed using LabChart 7 software (ADInstruments). LabChart Reader (ADInstruments) was used for initial data analysis. The graphs were prepared in Prism v9.0.1 (GraphPad) software.

**Statistical analysis**

Statistical analysis was performed using Prism v8.0.2 and v9.0.1 (GraphPad) software. Number of replicates, corresponding statistical tests, and statistically significant differences are indicated in figure legends. Statistically significant differences are indicated (*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001; ns, not significant). Data represent mean ± SD or SEM. Differences between groups were considered significant for *P ≤ 0.05.

**Data availability**

The cryo-EM densities for mouse (EMD-14627) and human (EMD-14626) ELP456 have been deposited in the EMDData Bank (EMDB). The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE (Perez-Riverol et al., 2022) partner repository with the dataset identifier PXD032925 (http://www.ebi.ac.uk/pride/archive/projects/PXD032925). The ELP4 and ELP6 variants identified in the patients have been deposited for public access within ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/) with accession numbers SCV002038507.1, SCV002038506.1 and SCV002498567. All other data generated in this study are available from corresponding authors on reasonable request.

**Expanded View** for this article is available online.

**Acknowledgements**

We thank all members of the Wainwright and Glatt laboratories for discussion and suggestions. We thank Sebastian Leidel for providing purified ncmU, mcmU and mcmA[U] nucleosides. This work was supported by the First Team Grant (FirstTEAM/2016-1/2; A.C.G. and S.G.) and the TEAM TECH CORE FACILITY/2017-4/6 grant from Foundation for Polish Science. This project has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement No 101003194). This research was supported in part by PLGrid infrastructure, and we thank all staff at the SOLARIS National Synchrotron Radiation Centre, Poland. This research was carried out at the Translational Research Institute, Woolloomooloo, QLD 4102, Australia. The Translational Research Institute is supported by a grant from the Australian Government. This work was supported by Scientific and Technological Research Council of Turkey (TÜBİTAK-BİDEB 2219 to S.C.; International Postdoctoral Research Scholarship Programme and TÜBİTAK BİDEB 2228-B to T.O.; National Scholarship Programme for Ph.D. Students) and a grant from the US National Institutes of Health (NIH R01 MH101221 to E.E.E.). Sequencing of ELP6 cases was provided by the University of Washington Center for Mendelian Genomics (UW-CMG) and was funded by the National Human Genome Research Institute (NHGRI) and the National Heart, Lung and Blood Institute (NHLBI) grants UMI HG006493 and U24 HG008956. This work has been supported with the Dokuz Eylül University Fund (grants 2018.KB.SAG.116 and 2012.KB.SAG.026 to SC). We would like to thank Ms Khadine Wilthshire for her help in the REB application process and drawing a pedigree for the ELP4 patient. The open-access publication of this article was funded by the Priority Research Area BioS under the program “Initiative of Excellence—Research University” at the Jagiellonian University in Krakow.

**Author contributions**

Monika Gaik: Conceptualization; Data curation; Formal analysis; Validation; Investigation; Visualization; Writing—original draft; Writing—review & editing.

Marija Kojic: Conceptualization; Data curation; Formal analysis; Validation; Investigation; Visualization; Writing—original draft; Writing—review & editing.

Megan R Stegeman: Data curation; Investigation; Methodology. Tolay Öncü-Öner: Data curation; Formal analysis; Validation; Investigation; Visualization; Methodology; Writing—review & editing. Anna Kościelniaik: Data curation; Investigation; Methodology. Alun Jones: Data curation; Investigation; Visualization; Methodology. Ahmed Mohamed: Data curation; Validation; Investigation; Visualization. Pak Yan Stefanie Chau: Data curation; Investigation; Methodology. Sazia Sharmin: Data curation; Investigation; Methodology.

**Data availability**

The cryo-EM densities for mouse (EMD-14627) and human (EMD-14626) ELP456 have been deposited in the EMDData Bank (EMDB). The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE (Perez-Riverol et al., 2022) partner repository with the dataset identifier PXD032925 (http://www.ebi.ac.uk/pride/archive/projects/PXD032925). The ELP4 and ELP6 variants identified in the patients have been deposited for public access within ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/) with accession numbers SCV002038507.1, SCV002038506.1 and SCV002498567. All other data generated in this study are available from corresponding authors on reasonable request.

**Expanded View** for this article is available online.

**Acknowledgements**

We thank all members of the Wainwright and Glatt laboratories for discussion and suggestions. We thank Sebastian Leidel for providing purified ncmU, mcmU and mcmA[U] nucleosides. This work was supported by the First Team Grant (FirstTEAM/2016-1/2; A.C.G. and S.G.) and the TEAM TECH CORE FACILITY/2017-4/6 grant from Foundation for Polish Science. This project has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement No 101003194). This research was supported in part by PLGrid infrastructure, and we thank all staff at the SOLARIS National Synchrotron Radiation Centre, Poland. This research was carried out at the Translational Research Institute, Woolloomooloo, QLD 4102, Australia. The Translational Research Institute is supported by a grant from the Australian Government. This work was supported by Scientific and Technological Research Council of Turkey (TÜBİTAK-BİDEB 2219 to S.C.; International Postdoctoral Research Scholarship Programme and TÜBİTAK BİDEB 2228-B to T.O.; National Scholarship Programme for Ph.D. Students) and a grant from the US National Institutes of Health (NIH R01 MH101221 to E.E.E.). Sequencing of ELP6 cases was provided by the University of Washington Center for Mendelian Genomics (UW-CMG) and was funded by the National Human Genome Research Institute (NHGRI) and the National Heart, Lung and Blood Institute (NHLBI) grants UMI HG006493 and U24 HG008956. This work has been supported with the Dokuz Eylül University Fund (grants 2018.KB.SAG.116 and 2012.KB.SAG.026 to SC). We would like to thank Ms Khadine Wilthshire for her help in the REB application process and drawing a pedigree for the ELP4 patient. The open-access publication of this article was funded by the Priority Research Area BioS under the program “Initiative of Excellence—Research University” at the Jagiellonian University in Krakow.

**Author contributions**

Monika Gaik: Conceptualization; Data curation; Formal analysis; Validation; Investigation; Visualization; Writing—original draft; Writing—review & editing.

Marija Kojic: Conceptualization; Data curation; Formal analysis; Validation; Investigation; Visualization; Writing—original draft; Writing—review & editing.

Megan R Stegeman: Data curation; Investigation; Methodology. Tolay Öncü-Öner: Data curation; Formal analysis; Validation; Investigation; Visualization; Methodology; Writing—review & editing. Anna Kościelniaik: Data curation; Investigation; Methodology. Alun Jones: Data curation; Investigation; Visualization; Methodology. Ahmed Mohamed: Data curation; Validation; Investigation; Visualization. Pak Yan Stefanie Chau: Data curation; Investigation; Methodology. Sazia Sharmin: Data curation; Investigation; Methodology. Andrzej Chramiec-Gląbik: Data curation; Funding acquisition; Investigation.

Paulina Indyka: Data curation; Investigation; Methodology. Michal Rawski: Data curation; Investigation; Methodology. Anna Biela: Data curation; Investigation; Methodology. Dominika Dobosz: Data curation; Investigation; Methodology. Amanda Millar: Data curation; Investigation; Methodology. Vann Chau: Data curation; Investigation; Methodology. Aycan Unalp: Resources. Michael Piper: Data curation; Investigation; Methodology. Mark C Bellingham: Data curation; Investigation; Visualization; Methodology. Evan E Eichert: Resources; Data curation; Supervision; Funding acquisition; Investigation. Deborah A Nickerson: Resources; Data curation; Funding acquisition; Investigation. Handan Cülyuz: Resources; Visualization. Nour El Hana Abbassi: Data curation; Investigation; Methodology. Melissa J Davis: Data curation; Investigation; Methodology. Saadet Mercimek-Andrews: Data curation; Investigation; Methodology. Sultan Cingöz: Conceptualization; Resources; Data curation; Formal analysis; Supervision; Funding acquisition; Validation; Investigation; Methodology. Project administration; Writing—review & editing. Brandon J Wainwright: Conceptualization; Data curation; Supervision; Validation; Investigation; Methodology; Writing—original draft; Project administration; Writing—review & editing. Sebastian Glatt: Conceptualization; Data curation; Formal analysis; Supervision; Funding acquisition; Validation; Investigation; Visualization; Methodology; Writing—original draft; Project administration; Writing—review & editing.

**Disclosure and competing interests statement**

The authors declare that they have no conflict of interest.

**References**


Karlsbom T, Tukenmez H, Chen C, Byström AS (2014) Familial dysautonomia (FD) patients have reduced levels of the modified wobble nucleoside mcm5–S–U in tRNA. Biochem Biophys Res Commun 454: 441–445


License: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.